Insulin resistance syndrome in a patient with limited cutaneous systemic sclerosis and type 2 diabetes and its response to plasma exchange, immunosuppression, and the Minimed® 780G continuous subcutaneous insulin infusion hybrid system
Revista Colombiana de Endocrinología, Diabetes & Metabolismo · 29.06.2026 · 13 (2)
DOI: 10.53853/encr.13.2.899 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista Colombiana de Endocrinología, Diabetes & Metabolismo, online erschienen am 29.06.2026. Verfasst von Fabio Nelson Figueroa Agudelo und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
Type B insulin resistance syndrome (TBIRS) is an immune-mediated disorder characterized by severe acanthosis nigricans and difficult-to-control diabetes mellitus. This condition represents a complex clinical challenge.
Objective
To describe the case of a patient compatible with Type B insulin resistance syndrome, highlighting the challenges in glycemic control and the response to immunosuppressive therapy combined with a hybrid continuous subcutaneous insulin infusion system. Case Presentation: A 57-year-old woman with a history of limited cutaneous systemic sclerosis and type 2 diabetes mellitus presented with severe insulin resistance, acanthosis nigricans, and markedly elevated blood glucose levels. Anti-insulin receptor antibodies were consistently negative. The patient received multiple treatments, including plasmapheresis, immunosuppressive therapy, and continuous subcutaneous insulin infusion using a MiniMed® 780G system, resulting in improved continuous glucose monitoring metrics and a reduction in daily insulin requirements.
Discussion
This case suggests a possible association between systemic sclerosis and Type B insulin resistance syndrome despite persistently negative anti-insulin receptor antibodies. A false-negative result may be explained by prior immunomodulatory treatments. The combination of immunosuppressive therapy and a hybrid closed-loop continuous subcutaneous insulin infusion system demonstrated favorable clinical outcomes.
Conclusion
This case report contributes to the. understanding of Type B insulin resistance syndrome and highlights the potential benefit of integrating immunosuppressive therapies with advanced insulin delivery technologies. Further studies are needed to define their role in the management of patients with severe insulin resistance
Zitieren
APA
Agudelo, F. N. F., Pico, V. M. B., Trujillo, A. O. G., Marín, J. W. T., Bonelo, K. M. F., Gómez, G. E. G., & Cañas, C. A. (2026). Insulin resistance syndrome in a patient with limited cutaneous systemic sclerosis and type 2 diabetes and its response to plasma exchange, immunosuppression, and the Minimed® 780G continuous subcutaneous insulin infusion hybrid system. Revista Colombiana de Endocrinología, Diabetes & Metabolismo, 13(2). https://doi.org/10.53853/encr.13.2.899
Vancouver
Agudelo FNF, Pico VMB, Trujillo AOG, Marín JWT, Bonelo KMF, Gómez GEG, et al. Insulin resistance syndrome in a patient with limited cutaneous systemic sclerosis and type 2 diabetes and its response to plasma exchange, immunosuppression, and the Minimed® 780G continuous subcutaneous insulin infusion hybrid system. Revista Colombiana de Endocrinología, Diabetes & Metabolismo. 2026;13(2). doi:10.53853/encr.13.2.899
BibTeX
@article{Agudelo2026,
author = {Agudelo, Fabio Nelson Figueroa and Pico, Víctor Manuel Blanco and Trujillo, Andrés Octavio García and Marín, Jorge Wilmar Tejada and Bonelo, Karen Milena Feriz and Gómez, Guillermo Edinson Guzmán and Cañas, Carlos Alberto},
title = {Insulin resistance syndrome in a patient with limited cutaneous systemic sclerosis and type 2 diabetes and its response to plasma exchange, immunosuppression, and the Minimed® 780G continuous subcutaneous insulin infusion hybrid system},
journal = {Revista Colombiana de Endocrinología, Diabetes & Metabolismo},
year = {2026},
volume = {13},
number = {2},
doi = {10.53853/encr.13.2.899}
}
EUVIMED